alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in theRegistration Statements (Form S-8 No. 333-13405, No. 333-81023 and No. 333-104280) pertaining to the Amended and Restated 1995 Equity Participation Plan of Ambassadors International, Inc. and in the Registration Statement (Form S-8No. 333-129404) pertaining to the 2005 Incentive Award Plan of Ambassadors International, Inc. of our reports dated March 2, 2006, with respect to the consolidated financial statements and schedule of Ambassadors International, Inc.,Ambassadors International, Inc. management’s assessment of the effectiveness of internal control over financial reporting, and the effectiveness of internal control over financial reporting of Ambassadors International, Inc., included in theAnnual Report (Form 10-K) for the year ended December 31, 2005. 

Our audits also included the financial statement schedule of AmbassadorsInternational, Inc. listed in Item 15(a). This schedule is the responsibility of Ambassadors International, Inc.’s management. Our responsibility is to express an opinion based on our audits. In our opinion, as to which the date isMarch 2, 2006, the financial statement schedule referred to above, when considered in relation to the basic financial statements taken as a whole, presents fairly in all material respects the information set forth therein. 

/s/ Ernst & Young LLP 

Irvine, California 

March 2, 2006
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1580 Phosphorus (inorganic) test system. ( a ) *Identification.* A phosphorus (inorganic) test system is a device intended to measure inorganic phosphorus in serum, plasma, and urine. Measurements of phosphorus (inorganic) are used in the diagnosis and treatment of various disorders, including parathyroid gland and kidney diseases, and vitamin D imbalance.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
[52 FR 16122, May 1, 1987, as amended at 84 FR 71796, Dec. 30, 2019]
Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER  Pursuant to 18 U.S.C. Section 1350, as adopted  Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

The undersigned, Kevin S. Herrmann, Chief Financial Officer of Ballantyne of Omaha, Inc. (the "Company"), has executed this
certification in connection with the filing with the Securities and Exchange Commission of the Company's Annual Report on Form 10-K for the year ended December 31, 2008 (the "Report").

The
undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to his knowledge
that:



IN
WITNESS WHEREOF, the undersigned has executed this certification as of the 16th day of March 2008.

/s/ KEVIN S. HERRMANN Kevin S. Herrmann
Chief Financial Officer


A
signed original of this written statement required by Section 906 has been provided to Ballantyne of Omaha, Inc. and will be retained by Ballantyne of Omaha, Inc. and furnished to the
Securities and Exchange Commission or its staff upon request.

---



QuickLinks
Michigan Supreme Court

Lansing, Michigan

Marilyn Kelly,

 Chief Justice

Michael F. Cavanagh

Elizabeth A. Weaver

Maura D. Corrigan

Robert P. Young, Jr.

Stephen J. Markman

Diane M. Hathaway, Justices

I, Corbin R. Davis, Clerk of the Michigan Supreme Court, certify that the 

foregoing is a true and complete copy of the order entered at the direction of the Court. 

 _________________________________________ 

 Clerk

September 11, 2009 

s0831 

Order 

 

September 11, 2009 

138760 

DARCY LYNN DEAN, 

Plaintiff-Appellee, 

v SC: 138760 

 COA: 288889 

Kent CC: 97-012933-DC 

GARY MICHAEL HENNING, 

Defendant-Appellant. 

_________________________________________/ 

 On order of the Court, the application for leave to appeal the March 19, 2009 order 

of the Court of Appeals is considered, and it is DENIED, because we are not persuaded 

that the question presented should be reviewed by this Court.
#### § 640.17 Modifications for specific products.

Red Blood Cells Frozen: A cryophylactic substance may be added to the Red Blood Cells for extended manufacturers' storage at −65 °C or colder, provided the manufacturer submits data considered by the Director, Center for Biologics Evaluation and Research, as adequately demonstrating through in vivo cell survival and other appropriate tests that the addition of the substance, the materials used and the processing methods results in a final product that meets the required standards of safety, purity, and potency for Red Blood Cells, and that the frozen product will maintain those properties for the prescribed dating period. Section 640.11 (a) and (b) do not apply while a cryophylactic substance is present.

[38 FR 32089, Nov. 20, 1973, as amended at 41 FR 18292, May 3, 1976; 49 FR 23834, June 8, 1984; 50 FR 4139, Jan. 29, 1985; 55 FR 11013, Mar. 26, 1990; 63 FR 16685, Apr. 6, 1998]
§ 74.2321 D&C Red No. 21. ( a ) *Identity and specifications.* The color additive D&C Red No. 21 shall conform in identity and specifications to the requirements of § 74.1321(a)(1) and (b).
( b ) *Uses and restrictions.* The color additive D&C Red No. 21 may be safely used for coloring cosmetics generally in amounts consistent with current good manufacturing practice.
( c ) *Labeling requirements.* The label of the color additive shall conform to the requirements of § 70.25 of this chapter.
( d ) *Certification.* All batches of D&C Red No. 21 shall be certified in accordance with regulations in part 80 of this chapter.
[47 FR 53846, Nov. 30, 1982]
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7606 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7606

 To designate the facility of the United States Postal Service located 
 at 1087 Route 47 South in Rio Grande, New Jersey, as the ``Carlton H. 
                      Hand Post Office Building''.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 8, 2024

  Mr. Van Drew (for himself, Mr. Smith of New Jersey, Mr. Kean of New 
   Jersey, Mr. Norcross, Mr. Kim of New Jersey, Mr. Gottheimer, Mr. 
Pallone, Mr. Menendez, Mr. Pascrell, Mr. Payne, Ms. Sherrill, and Mrs. 
 Watson Coleman) introduced the following bill; which was referred to 
             the Committee on Oversight and Accountability

_______________________________________________________________________

                                 A BILL

 
 To designate the facility of the United States Postal Service located 
 at 1087 Route 47 South in Rio Grande, New Jersey, as the ``Carlton H. 
                      Hand Post Office Building''.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. CARLTON H. HAND POST OFFICE BUILDING.

    (a) Designation.--The facility of the United States Postal Service 
located at 1087 Route 47 South in Rio Grande, New Jersey, shall be 
known and designated as the ``Carlton H. Hand Post Office Building''.
    (b) References.--Any reference in a law, map, regulation, document, 
paper, or other record of the United States to the facility referred to 
in subsection (a) shall be deemed to be a reference to the ``Carlton H. 
Hand Post Office Building''.
                                 <all>
```
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
     Financial Data Schedule of March 31, 2000 - Healthcare Properties, L.P.
</LEGEND>
<CIK>                         0000814458
<NAME>                        Healthcare Properties, L.P.
<MULTIPLIER>                  1
<CURRENCY>                    U.S. Dollars

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>               DEC-31-2000
<PERIOD-START>                  JAN-01-2000
<PERIOD-END>                    MAR-31-2000
<EXCHANGE-RATE>                 1
<CASH>                          17,577,257
<SECURITIES>                    0
<RECEIVABLES>                   1,452,747
<ALLOWANCES>                    (729,310)
<INVENTORY>                     0
<CURRENT-ASSETS>                0
<PP&E>                          23,437,241
<DEPRECIATION>                  (9,038,846)
<TOTAL-ASSETS>                  32,923,670
<CURRENT-LIABILITIES>           0
<BONDS>                         0
<PREFERRED-MANDATORY>           0
<PREFERRED>                     0
<COMMON>                        0
<OTHER-SE>                      27,340,961
<TOTAL-LIABILITY-AND-EQUITY>    32,923,670
<SALES>                         0
<TOTAL-REVENUES>                2,919,461
<CGS>                           0
<TOTAL-COSTS>                   1,701,414
<OTHER-EXPENSES>                34,319
<LOSS-PROVISION>                0
<INTEREST-EXPENSE>              132,189
<INCOME-PRETAX>                 1,051,539
<INCOME-TAX>                    0
<INCOME-CONTINUING>             0
<DISCONTINUED>                  0
<EXTRAORDINARY>                 0
<CHANGES>                       0
<NET-INCOME>                    1,051,539
<EPS-BASIC>                     .25
<EPS-DILUTED>                   .25



</TABLE>
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          SEP-30-1996
<PERIOD-START>                             OCT-01-1995
<PERIOD-END>                               SEP-30-1996
<CASH>                                          61,107
<SECURITIES>                                         0
<RECEIVABLES>                                    5,977
<ALLOWANCES>                                     3,735
<INVENTORY>                                        604
<CURRENT-ASSETS>                                68,158
<PP&E>                                           6,400
<DEPRECIATION>                                   2,955
<TOTAL-ASSETS>                                  71,608
<CURRENT-LIABILITIES>                           16,235
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        45,688
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                    71,608
<SALES>                                         59,699
<TOTAL-REVENUES>                                59,699
<CGS>                                            8,701
<TOTAL-COSTS>                                    8,701
<OTHER-EXPENSES>                                36,425
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                  72
<INCOME-PRETAX>                                 16,073
<INCOME-TAX>                                     4,982
<INCOME-CONTINUING>                             11,091
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    11,091
<EPS-PRIMARY>                                     0.76
<EPS-DILUTED>                                     0.76
        

</TABLE>
- 796 -

Nebraska Supreme Court Advance S

296 Nebraska Report

STATE v. SCHIESSER

Cite as 296 Neb. 796

State of Nebraska, appellee, v.

Michael R. Schiesser, appe

___ N.W.2d ___

Filed June 2, 2017. No. S-16-115.

Petition for further review from the Court of Appeals, 

Inbody, Riedmann, and Bishop, Judges, on appeal thereto

the District Court for Lancaster County, Lori A. Maret, Judg

Judgment of Court of Appeals affirmed.

John S. Berry, of Berry Law Firm, for appellant.

Douglas J. Peterson, Attorney General, Melissa R. Vincent, 

and, on brief, George R. Love for appellee.

Heavican, C.J., Wright, Miller-Lerman, Cassel,

Kelch, and Funke,

Per Curiam

Having reviewed the briefs and record and having heard 

oral arguments, we conclude on further review that the decision of the Nebraska Court of Appeals in State v. Schiesser, 24 

Neb. App. 407, 888 N.W.2d 736 (2016), is correct, and accordingly, we affirm the decision of the Court of Appeals which 

affirmed the judgment of the district court.

Affirmed

Nebraska Supreme Court Online Library

www.nebraska.gov/apps-courts-epub/

07/21/2017 08:11 AM CDT
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.1342 Reverse central venous recanalization system. ( a ) *Identification.* A reverse central venous recanalization system is a prescription device for obtaining central venous access to facilitate catheter insertion into the central venous system. Reverse recanalization involves the initiation of an access path from within the vein and then progressing to the skin for patients with upper body venous occlusions or other conditions that preclude central venous access by other methods.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Clinical performance testing must fulfill the following: ( i ) Demonstrate the ability to safely deliver, deploy, and remove the device; and
( ii ) Evaluate all adverse events including death, bleeding, damage to non-target tissue and organs, blood vessel perforation or rupture, and hematoma.
( 2 ) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested: ( i ) Simulated-use testing in a clinically relevant bench anatomic model to assess the delivery, deployment, and retrieval of the system;
( ii ) Compatibility with other devices labeled for use with the device;
( iii ) Tensile strengths of joints and components;
( iv ) Kink resistance of system components;
( v ) Radiopacity of components used to monitor procedure under fluoroscopy;
( vi ) Characterization and verification of all dimensions; and
( vii ) Leakage of air or fluid.
( 3 ) All patient contacting components of the device must be demonstrated to be biocompatible.
( 4 ) Performance data must demonstrate the sterility of the device components intended to be provided sterile.
( 5 ) Performance data must support the shelf life of the device by demonstrating continued sterility, package integrity, and device functionality over the identified shelf life.
( 6 ) Labeling for the device must include: ( i ) Instructions for use, including a description of compatible devices;
( ii ) A detailed summary of the clinical testing conducted and;
( iii ) Shelf life and storage conditions.
[87 FR 26991, May 6, 2022]
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.8175 Calibrator for platelet counting. ( a ) *Identification.* A calibrator for platelet counting is a device that resembles platelets in plasma or whole blood and that is used to set a platelet counting instrument. It is a suspension of particles or cells whose size, shape concentration, and other characteristics have been precisely and accurately determined.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.
[45 FR 60633, Sept. 12, 1980, as amended at 84 FR 71800, Dec. 30, 2019]
Exhibit 31.3
 CERTIFICATIONS
 
 I, W. Thomas Amick, certify that:
 
 1.           I have reviewed this Amendment No. 1 on Form 10-K/A for the fiscal year ended December 31, 2010 of Discovery Laboratories, Inc.; and
 
 2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
 
 
 Date:  April 29, 2011

/s/ W. Thomas AmickW. Thomas AmickChairman of the Boardand Chief Executive Officer
<PAGE>   1

                                                                    EXHIBIT 13
INDEPENDENT PUBLIC ACCOUNTANTS' REVIEW REPORT


To the Board of Directors of
Essef Corporation
Chardon, Ohio


We have reviewed the accompanying condensed consolidated balance sheet of Essef
Corporation and Subsidiaries (the "Company) as of December 31, 1996, and the
related condensed consolidated statements of operations for the three-month
periods ended December 31, 1996 and 1995 and the related condensed consolidated
statements of cash flows for the three-month periods ended December 31, 1996 and
1995. These financial statements are the responsibility of the Company's
management.

We conducted our reviews in accordance with standards established by the
American Institute of Certified Public Accountants. A review of interim
financial information consists principally of applying analytical procedures to
financial data and making inquiries of persons responsible for financial and
accounting matters. It is substantially less in scope than an audit conducted in
accordance with generally accepted auditing standards, the objective of which is
the expression of an opinion regarding the financial statements taken as a
whole. Accordingly, we do not express such an opinion.

Based on our reviews, we are not aware of any material modifications that should
be made to such condensed consolidated financial statements for them to be in
conformity with generally accepted accounting principles.

We have previously audited, in accordance with generally accepted auditing
standards, the consolidated balance sheet of the Company as of September 30,
1996, and the related consolidated statements of operations, stockholders'
equity, and cash flows for the year then ended (not presented herein) and in our
report dated November 19, 1996, we expressed an unqualified opinion on those
consolidated financial statements. In our opinion, the information set forth in
the accompanying condensed consolidated balance sheet as of September 30, 1996
is fairly stated, in all material respects, in relation to the consolidated
balance sheet from which it has been derived.





DELOITTE & TOUCHE


Cleveland, Ohio
January 23, 1997


                                  Page 15 of 16
**EXHIBIT
      32.2**


**CERTIFICATION
      PURSUANT TO 18 U.S.C. SECTION 1350,**


**AS
      ADOPTED PURSUANT TO SECTION 906 OF THE**


**SARBANES-OXLEY
      ACT OF 2002**





In 
      connection  with the quarterly report of Avitar,  Inc. (the 
"Company") on Form10-QSB for the period ending June 30, 2007 as filed with
      the
      Securities and Exchange  Commission on the date hereof (the 
"Report"),  I, Jay C. Leatherman,  Jr., Chief Financial 
Officer of the Company  certify,  pursuant to 18 U.S.C. Section
      1350, as adopted pursuant to Section 906 of the  Sarbanes-Oxley Act of
      2002, to my knowledge,


that:





(1) The Report fully  complies  with the  requirements  of
      Section 13(a) or15(d) of the Securities Exchange Act of 1934; and





(2)  The  information  contained  in the  Report 
fairly  presents,  in all material  respects,  the 
financial  condition  and results of operations of the
      Company.





Date:
      August 14, 2007





/s/ Jay C. Leatherman, Jr.


---------------------------------


Jay
      C. Leatherman, Jr.


Chief
      Financial Officer (Principal Financial
EXHIBIT 4.1

                                   RESOLUTIONS

      WHEREAS, the Company is indebted to Michael Segundo for services rendered
and expenses incurred in connection with the business of the Company.

RESOLVED, that in payment for services rendered and expenses incurred in
connection with the business of the Company the Company hereby grants to Michael
Segundo 700,000 shares of the Company's common stock, valued at $.13 per share,
to be registered in a registration statement on Form S-8 to be filed with the
Securities and Exchange Commission ("SEC") promptly after the Company becomes
current in all if its filing obligations under the Securities Exchange Act of
1934 (the "Exchange Act").
### THE THIRTEENTH COURT OF APPEALS

13

- 13

- 00500

- CR

GREGORY FONSECA

v. THE STATE OF TEXAS

On Appeal from the 2nd 25th District Court of Gonzales County , Texas

Trial Cause No. 80

- 12

- A

JUDGMENT THE THIRTEENTH COURT OF APPEALS, having considered this caus e on appeal, concludes that the judgment of the trial court should be affirmed as modified by
this Court . The Court orders the judgment of the trial court AFFIRMED AS MODIFIED

. We further order this decision certified below for observance.

November 13, 20 14
<PAGE>   1


                             EPL Technologies, Inc.


                                  EXHIBIT 11.0

                 Computation of Basic Earnings per Common Share
                     and Diluted Earnings per Common Share




<PAGE>   2







                                  EXHIBIT 11.0

EPL TECHNOLOGIES, INC.

COMPUTATION OF BASIC LOSS PER COMMON SHARE AND
DILUTED LOSS PER COMMON SHARE
(in thousands except per share data)
--------------------------------------------------------------

<TABLE>
<CAPTION>
                                             Twelve Months Ended December 31,
                                             --------------------------------
                                               1997       1996       1995
                                             ---------  ---------  ---------
<S>                                          <C>        <C>        <C>
Net loss                                      $(7,187)   $(4,296)   $(3,320)

Deduct:
Accretion, discount and dividends
on preferred stock                              1,168        999        314
                                             --------    -------    -------

Net loss for common shareholders              $(8,355)   $(5,295)   $(3,634)
                                             ========    =======    =======

Weighted average number
  of common shares outstanding                  8,373      7,437      4,656
                                              =======    =======    =======

Basic loss per share                          $ (1.00)   $ (0.71)   $ (0.78)
                                              =======    =======    =======

Net loss for diluted loss
per share computation                         $(7,187)   $(4,296)   $(3,320)

Weighted average number
  of common shares outstanding                  8,373      7,437      4,656

Common share equivalent applicable to:
 Series A convertible preferred stock           1,540      1,751      2,136
 Series B convertible preferred stock             169        118
 Series C convertible preferred stock              49
 Series D convertible preferred stock             178
 Series A warrants                                100        128        157
 Series D warrants                                 28
 Other warrants                                    96        243        706
 Stock options                                  1,574      1,196        746
Less common stock acquired
 with net proceeds                                982        597      1,545
                                             --------    -------    -------

Weighted average number of common shares
 and common share equivalent used to compute
 diluted loss per share                        11,125     10,276      6,856
                                              =======    =======    =======

Diluted loss per share                         $(0.65)   $ (0.42)    $(0.48)
                                              =======    =======    =======
</TABLE>